Real-world treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A retrospective chart study

被引：0
|
作者：
Guillaume, Xavier
Horchi, Dahbia
Gomez, Jorge
Hlavacek, Patrick
Ren, Jinma
Schepart, Alex
Aydin, Didem
DiBonaventura, Marco
机构：
[1] Cerner Enviza, Paris, France
[2] Pfizer Inc, New York, NY USA
[3] Pfizer Inc, Collegeville, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18826
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study
    Wang, Peter Feng
    Yee, Christopher W.
    Gorsh, Boris
    Zichlin, Miriam L.
    Paka, Prani
    Bhak, Rachel H.
    Boytsov, Natalie
    Khanal, Anamika
    Noman, Ahmed
    DerSarkissian, Maral
    Ferrante, Shannon
    Duh, Mei Sheng
    LEUKEMIA & LYMPHOMA, 2023, 64 (02) : 398 - 406
  • [32] Real-World Treatment Patterns and Outcomes of Daratumumab Retreatment in Multiple Myeloma in the United States
    Girvan, Allicia
    Yu, Junhua
    Emechebe, Nnadozie
    Kamalakar, Rajesh
    Luo, Yan
    BLOOD, 2022, 140 : 5266 - 5267
  • [33] Real-World Multiple Myeloma Treatment Patterns By Patient Characteristics and Outcomes in the United States
    Richter, Joshua
    Singh, Erin
    Rice, Megan S.
    BLOOD, 2021, 138
  • [34] Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma
    Bruno, Amanda S.
    Willson, Jenny L.
    Opalinska, Joanna M.
    Nelson, Jeanenne J.
    Lunacsek, Orsolya E.
    Stafkey-Mailey, Dana R.
    Willey, Joanne P.
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (09) : 1017 - 1025
  • [35] Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech
    Maisnar, Vladimir
    Pour, Ludek
    Spicka, Ivan
    Jelinek, Tomas
    Minarik, Jiri
    Jungova, Alexandra
    Stork, Martin
    Straub, Jan
    Radocha, Jakub
    Pika, Tomas
    Pospisilova, Lenka
    Nair, Sandhya
    Kunovszki, Peter
    Hajek, Roman
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (02): : 145 - 153
  • [36] REAL-WORLD PRESCRIBING PATTERNS IN US MULTIPLE MYELOMA (MM) PATIENTS REFRACTORY TO LENALIDOMIDE IN THE FRONT-LINE
    Jhaveri, M.
    Romanus, D.
    Raju, A.
    Seal, B.
    Farrelly, E.
    Yong, C.
    Noga, S.
    Labotka, R.
    Blazer, M.
    Parameswaran, H.
    HAEMATOLOGICA, 2016, 101 : 543 - 544
  • [37] Real-world assessment of the treatment patterns and outcomes among patients with multiple myeloma across different risk stratification criteria in the United States: a retrospective cohort study
    Rahman, Motiur
    Keegan, Alissa
    Mateus, Jazmine
    Kim, Christopher
    LEUKEMIA & LYMPHOMA, 2023, 64 (02) : 388 - 397
  • [38] Real-World Costs, Health Care Resource Utilization (HCRU), and Outcomes Among Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) in the US
    Nair, S.
    Lin, X.
    Potluri, R.
    Slavcev, M.
    Marshall, A.
    VALUE IN HEALTH, 2022, 25 (12) : S152 - S152
  • [39] Updated Comparative Effectiveness of Talquetamab vs Real-world Physician's Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
    Ye, Jing Christine
    Biran, Noa
    Nair, Sandhya
    Lin, Xiwu
    Qi, Keqin
    Ammann, Eric
    Renaud, Thomas
    Kane, Colleen
    Parekh, Trilok
    Gray, Kathleen
    Zhang, Xinke
    Costa, Luciano
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S99 - S100
  • [40] Evolving Real-World Treatment Patterns in Patients with Newly-Diagnosed Multiple Myeloma (NDMM) in the United States (US)
    Ailawadhi, Sikander
    Romanus, Dorothy
    Cherepanov, Dasha
    Yin, Yu
    Cheng, Meng-Ru
    Hari, Parameswaran
    BLOOD, 2019, 134
12345